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A B S T R A C T   
The current emergency of the novel coronavirus SARS-CoV2 urged the need for broad-spectrum antiviral drugs as 
the first line of treatment. Coronaviruses are a large family of viruses that already challenged humanity in at least 
two other previous outbreaks and are likely to be a constant threat for the future. In this work we developed a 
pipeline based on in silico docking of known drugs on SARS-CoV1/2 RNA-dependent RNA polymerase combined 
with in vitro antiviral assays on both SARS-CoV2 and the common cold human coronavirus HCoV-OC43. Results 
showed that certain drugs displayed activity for both viruses at a similar inhibitory concentration, while others 
were specific. In particular, the antipsychotic drug lurasidone and the antiviral drug elbasvir showed promising 
activity in the low micromolar range against both viruses with good selectivity index.   
1. Introduction 
The growth in human and animal population density through ur-
banization and agricultural development, combined with increased 
mobility and commercial transportation, land perturbation and climate 
change, all have an impact on virus emergence and epidemiology. Over 
the past decades, emerging zoonotic RNA viruses continuously gripped 
the world’s attention, either briefly (like the severe acute respiratory 
syndrome coronavirus, SARS-CoV1, in 2003), or continuously. Many 
RNA virus threats were considered as re-emerging including Dengue, 
Zika, Ebola, and Chikungunya virus, and current consensus predicts that 
novel and potentially highly pathogenic agents will continue to emerge 
from the large, genetically variable natural pools present in the envi-
ronment. CoVs are of particular concern due to high case-fatality rates, 
lack of therapeutics as well as the ability to seed outbreaks that rapidly 
cross geographic borders. A large number of highly diverse CoVs have 
been identified in animal hosts and especially in bat species, where they 
may have the potential to diffuse in other species including humans (Fan 
et al., 2019). 
CoVs consist of a large and diverse family of viruses that cause 
multiple respiratory, gastrointestinal and neurologic diseases of varying 
severity, including the common cold, bronchiolitis, and pneumonia 
(Weiss and Leibowitz, 2011). The CoV family is divided into four genera 
(alpha, beta, gamma, and delta) and thus far human CoV are limited to 
the alpha (HCoV-229E and HCoV-NL63) and beta genera (HCoV-OC43, 
HCoV-HKU1); the latter includes SARS-CoV1 and the Middle East res-
piratory syndrome coronavirus (MERS-CoV). A new previously un-
known coronavirus, named SARS-CoV2, was discovered in December 
2019 in Wuhan (Hubei province of China) and sequenced by January 
2020 (Lu et al., 2020). SARS-CoV2 is associated with an ongoing 
outbreak of atypical pneumonia (COVID-19), and was declared as 
’Public Health Emergency of International Concern’ on January 30th, 
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2020 by the World Health Organization (www.who.int). 
Currently, for the COVID19 outbreak, many known drugs are under 
clinical investigation (Kupferschmidt, 2020) (Magro, 2020), following 
different general principles and mechanisms of action: 1. the control of 
cytokine storms due to the hyper-reaction of the immune system against 
the virus (e.g. corticosteroids (Salton et al., 2020)); 2. the control of 
coagulopathy (e.g. heparin) 3. the inhibition of viral RNA dependent 
RNA polymerase (RdRp; e.g. prodrugs favipiravir and remdesivir); 4. the 
inhibition of viral entry (e.g. hydroxychloroquine); 5. the inhibition of 
the viral main protease (e.g. lopinavir and ritonavir); 6. the inhibition of 
viral attachment (the viral receptor ACE2 antagonist losartan). 
Despite their species diversity, CoVs share key genomic elements that 
are essential for viral replication, suggesting the possibility to design 
broad spectrum therapeutic agents to address the current epidemic and 
manage possible future outbreaks. The target considered in this work to 
identify new inhibitors is the highly conserved RdRp, that plays a crucial 
role in CoV replication cycle, catalyzing the synthesis of new viral RNA 
(Te Velthuis et al., 2012). The cryo-EM structure of SARS-CoV1 and 
SARS-CoV2 RdRp, bound to nsp7 and nsp8 co-factors, have been 
recently solved (PDB-id: 6NUR (Kirchdoerfer and Ward, 2019), and 
6M71 (Gao et al., 2020), respectively). The two proteins share a 
sequence identity of 96% (98% conservative substitution) and a struc-
tural r.m.s.d. of 0.54 Å (considering 788 Cαs). 
The exploration of libraries of molecules already in use as human 
drugs and well characterized in terms of human metabolism might allow 
the identification of antivirals that could be, in principle, rapidly tested 
in patients. Accordingly, we chose to analyze in silico the public database 
of approved/investigational drugs (DrugBank library, https://go.drug 
bank.com/), targeting a wide region around the active site of SARS- 
CoV1 RdRp. The computational work allowed the selection of 13 
commercially available compounds with predicted high affinity for the 
protein and favorable solubility properties. These potential inhibitors 
(together with suramin, known to inhibit several RNA viruses) have 
been tested in cell-based assays against SARS-CoV2 and HCoV-OC43 (Su 
et al., 2016), revealing moderate to high antiviral activities for seven of 
them. Our results confirm antiviral properties already described for 
some of the selected compounds, and, more importantly, show new 
interesting properties for the compounds lurasidone and elbasvir as 
beta-CoV inhibitors. 
2. Materials and Methods 
2.1. In silico docking 
The virtual Library of DrugBank (https://go.drugbank.com/) 
employed for the docking analysis includes FDA-approved drugs as well 
as experimental drugs going through the FDA approval process. Starting 
from the 2D sdf structures of the library (7180 molecules), we filtered 
out all the molecules with Mw ≥ 900 Da (keeping 7025 molecules) and 
then added explicit hydrogens (at pH 7.4) with the program Open Babel 
(O’Boyle et al., 2011). Next, we used the program Molconvert (htt 
ps://chemaxon.com/) to obtain a low energy 3D conformer for most 
of the molecules (6996 compounds) that were finally transformed into 
the AutoDock4 pdbqt format (adding charges and defining rotational 
freedom) with the AutoDockTools package (http://mgltools.scripps. 
edu). 
The atomic coordinates of SARS-CoV1 RdRp (PDB-id: 6NUR) bound 
to NSP7 and NSP8 co-factors, were chosen as docking model for CoV 
polymerase. Hydrogen atoms and Kollman charges (Singh and Kollman, 
1984) were added using the program Python Molecule Viewer 1.5.4 
(MGL-tools package http://mgltools.scripps.edu/). The protein model 
was then used to build a discrete grid within a box of dimensions 22.5 ×
26.3 × 22.5 Å3 (program AutoGrid (Goodford, 1985)) as the explored 
volume for both the AutoDock4.2 and AutoDock Vina searches. The grid 
was centered near the side chain of Lys545, to include a wide region 
around the protein active site. During the computational analysis, the 
protein was constrained as rigid, whereas the small molecules were free 
to move. The in silico screen was divided into two runs: a fast procedure 
using the program AutoDock Vina (Trott and Olson, 2009) for the se-
lection of the best compounds, followed by a more accurate screen using 
the program AutoDock4.2 (Morris et al., 2009). The AutoDock Vina 
docking search (energy_range = 4; num_modes = 4 exhaustiveness = 10) 
produced a ranked list of all compounds, with predicted binding free 
energy values (ΔG) ranging between − 0.9 kcal/mol and − 8.9 kcal/mol. 
The best 118 compounds (~2% of the library, ΔG between − 8.9 and 
− 7.6 kcal/mol) were further analyzed using AutoDock4.2 (Morris et al., 
2009), with 80 hybrid GA-LS genetic algorithm runs (ga_num_evals =
1750000, ga_pop_size = 150). Among the molecules with higher pre-
dicted affinity for RdRp (ΔG values varying between − 4.67 and − 11.7 
kcal/mol), 13 FDA approved drugs were selected, taking into account 
commercial availability and solubility (as suggested by the theoretical 
logP values in the DrugBank library) properties, for in vitro assays. To 
confirm the binding of the 13 selected compounds to the recently 
released SARS-CoV2 RdRp we performed an additional in silico docking 
using as model the structure of Gao et al. (PDB-id: 6m71 (Gao et al., 
2020)) with 300 hybrid GA-LS genetic algorithm runs. Furthermore, 
since among such drugs were present known inhibitors of viral protease 
we investigated in silico their binding affinity for CoV main protease 
(PDB-id: 6LU7 (Jin et al., 2020)). Briefly, we explored with AutoDock4.2 
a region of 15 × 22.5 × 22.5 Å3 (after mutating the active site Cys145 to 
Ala) centered between the side chains of Asn142 and Gln189 to cover 
the whole cavity in front of the protease active site. We used the same 
docking procedure as described for the RdRp. 
2.2. SARS-CoV2 cell based assays 
2.2.1. Cell lines and viruses 
Vero E6 cells (ATCC-1586), the human hepatocarcinoma Huh7 cells 
kindly provided by Ralf Bartenschlager (University of Heidelberg, Ger-
many) and Huh 7 engineering by lentivirus transduction to overexpress 
the human ACE2 (Huh7-hACE2) were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS, Gibco). Working stocks of SARS-CoV2 ICGEB-FVG_5 isolated in 
Trieste, Italy, were routinely propagated and titrated on Vero E6 cells 
(Licastro et al., 2020). 
2.2.2. Compounds preparation 
Compounds were prepared in 2-fold serial dilutions (8 points di-
lutions) in DMSO, and then diluted 16x in PBS in an intermediate plate. 
Finally, compounds were transferred to the 96 well assay plate con-
taining cells and virus medium (6x in grown medium, final dilution 
100x). 
2.2.3. High Content Assay 
Huh 7- hACE2 cells were seeded in a 96 wells’ plate, at 8 × 103 cells/ 
well density and incubated at 37 ◦C overnight. Cells were treated with 
serial dilution of the compounds and then infected with SARS-CoV2 at 
0.1 MOI. Controls included: positive controls like infected cells treated 
with 50 μM of Hydroxychloroquine as well as non-infected cells treated 
with vehicle (1% DMSO), and negative controls such as infected cells 
treated with vehicle. Plates were incubated for 20 h at 37 ◦C, and then 
fixed with 4% PFA (Paraformaldehyde) for 20 min at room temperature 
and washed twice with PBS 1x. Cells were treated with 0.1% of Triton-X 
for 15 min, followed incubation of 30 min in blocking buffer (PBS 1x 
containing 1% of bovine serum albumin-BSA). Then, a primary recom-
binant monoclonal Spike antibody (CR3022) was diluted in blocking 
buffer and incubate for 2 h at 37 ◦C (Rajasekharan et al., 2020). Cells 
were washed 2 times in PBS 1x and incubated with the secondary 
antibody AlexaFluor488-conjugated goat anti-mouse IgG (Cat No. 
A-11001, Thermo-Scientific) plus 4’,6-diamidino-2-phenylindole 
(DAPI) for 1 h at 37 ◦C. Each plate was washed twice with PBS 1x. All 
plates were filled up with 150 μl of PBS/well. Digital images were 
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acquired using a high content imaging system, the Operetta (Perki-
nElmer). The digital images were taken from 9 different fields of each 
well at 20× magnification. Total number of cells and the number of 
infected cells were analysis using Columbus Image Data Storage and 
Analysis System (PerkinElmer). 
2.2.4. Cytotoxicity assay 
The cytotoxicity assay was conducted with Alamar Blue (Invitrogen) 
as recommended by the manufacturer’s protocol. Huh7-hACE2 cells 
were seeded at 8 × 103 cells per well in a 96 well plate, and incubated at 
37 ◦C overnight. Then 50 μL of compound at the indicated concentra-
tions were added to 150 μL of medium (final 200 μL). Plates were 
incubating at 37 ◦C for 20 h and then the colorimetric reagent was added 
(20 μL for 8 h). Measurements from compound treated cells were 
normalized against those from untreated cells. 
2.2.5. Virus yield reduction assay 
Huh7-hACE2 were seeded into a 12-well plate 24 h prior infection. 
Cells were infected with SARS-CoV2 at MOI 0.1 and simultaneously 
treated in 2-fold serial dilutions of compound. After 1 h infection, cells 
were washed with PBS 1x, and incubated in medium containing 2% FBS 
and the indicated compounds. Cell culture supernatants were collected 
after 20 h, virus titers were determined in duplicate by a plaque assay in 
Vero E6 cells. Values of virus titer (Log pfu/ml) from each sample were 
calculated and reported. To obtained the % of inhibition, values of 
infected-treated samples were normalized with values of the not-treated 
infected samples control. The half maximal effective concentrations 
(EC50) were calculate using GraphPad Prism Version 7. 
2.2.6. Data normalization and analysis 
Infection ration was defined as ratio between (i) the total number of 
infected cells, and (ii) the total number of cells. Data were normalized 
with the negative (DMSO-treated, infected cells) and positive (50 μM 
Hydroxychloroquine, treated infected cells) controls. Percentage inhi-
bition was calculated based on infection ratio values with the formula: 
(1-(infection ratio samples – Average (Av) infection ratio of positive 
control)/(Av. infection ratio of negative control – Av. infection ratio of 
positive control)) x100. Percentage of nuclei was calculated from values 
of cell number with the formula: (Cell number test sample/Av. cell 
number of positive control) × 100. Values were plotted against dilutions 
expressed as antilog. The half maximal effective concentration (EC50) 
and the half maximum cytotoxic concentration (CC50) were calculated 
using GraphPad Prism Version 7. 
2.3. HCoV-OC43 cell-based assays 
2.3.1. Reagents 
Dimethyl sulfoxide (DMSO) was purchased from Sigma-Aldrich 
(Saint Louis, MO). The mouse anti-coronavirus monoclonal antibody 
MAB9013 was purchased from Merck (Darmstadt, Germany). The sec-
ondary antibody peroxidase-conjugated AffiniPure F(ab’)2 Fragment 
Goat Anti-Mouse IgG (H + L) was purchased from Jackson ImmunoR-
esearch Laboratories Inc. (West Grove, PA, USA). 
2.3.2. Cell lines and viruses 
Human lung fibroblast cells MRC-5 (ATCC® CCL-171) were propa-
gated in Dulbecco’s Modified Eagle Medium (DMEM; Sigma, St. Louis, 
MO, USA) supplemented with 1% (v/v) penicillin/streptomycin solution 
(Euroclone, Milan, Italy) and heat inactivated, 10% (v/v) fetal bovine 
serum (Sigma). Human coronavirus strain OC43 (HCoV–OC43) (ATCC® 
VR-1558) was purchased from ATCC (American Type Culture Collec-
tion, Rockville, MD, USA). The virus was propagated in MRC-5 cells at 
33 ◦C, in a humidified 5% CO2 incubator, and titrated by standard 
plaque method on MRC-5 cells, as described elsewhere (Marcello et al., 
2020); titers were expressed in terms of plaque forming units per ml 
(PFU/ml). 
2.3.3. Cell viability assay 
Cell viability was measured using the MTS assay, as described else-
where (Lembo et al., 2014). MRC-5 cells were seeded at a density of 2 ×
104 cells/well in 96-well plates and treated the next day with com-
pounds at concentrations ranging from 1000 to 0.05 μM, under the same 
experimental conditions described for the antiviral assays. Treatment of 
control wells with equal volumes of DMSO was performed in order to 
rule out the possibility of any cytotoxic effect ascribable to the solvent. 
After 20 h of incubation, cell viability was determined using the Cell 
Titer 96 Proliferation Assay Kit (Promega, Madison, WI, USA) according 
to the manufacturer’s instructions. Absorbances were measured using a 
Microplate Reader (Model 680, Bio-Rad Laboratories, Hercules, CA, 
USA) at 490 nm. The effect on cell viability at different concentrations of 
compounds was expressed as a percentage, by comparing absorbances of 
treated cells with those of cells incubated with culture medium and 
equal volumes of DMSO. The 50% cytotoxic concentrations (CC50) and 
standard deviation (SD) values were determined using GraphPad Prism 
5.0 software (GraphPad Software, San Diego, CA). 
2.3.4. Antiviral assay 
The antiviral activity was determined by focus reduction assay. MRC- 
5 cells were seeded, at 2 × 104 cells/well density, in 96-well plates and 
incubated at 37 ◦C overnight. The next day, the medium was removed 
from the plates and infection was performed with ca. 40 PFU of a stock of 
HCoV-OC43 (MOI 0.2 PFU/cells) in presence of serial dilutions of 
compounds, ranging from 100 to 0.005 μM. Control wells were infected 
in presence of equal volumes of DMSO. After 20 h of incubation at 33 ◦C 
in a humified 5% CO2 atmosphere, cells were fixed with cold acetone- 
methanol (50:50) and subjected to indirect immunostaining by using 
an anti-coronavirus monoclonal antibody (MAB9013). The number of 
immunostained foci was counted, and the percent inhibition of virus 
infectivity was determined by comparing the number of foci in treated 
wells with the number in untreated control wells. The focus reduction 
assays were conducted in three independent experiments. Where 
possible, half-maximal antiviral effective concentration (EC50) and SD 
values were calculated by regression analysis using the software 
GraphPad Prism 5.0 (GraphPad Software, San Diego, CA) by fitting a 
variable slope-sigmoidal dose–response curve. 
2.3.5. Virus yield reduction assay 
MRC5 cells were seeded in 24-well plates at a density of 2 × 105 
cells/well and grown overnight at 37 ◦C. The next day, infection was 
performed with HCoV-OC43 at a MOI of 0.02 PFU/cells in the presence 
of serial dilutions of compound, ranging from 100 to 0.006 μM. 
Following adsorption at 33 ◦C for 1 h, the virus inoculum was removed 
and cells were grown in presence of compound. Supernatants were 
harvested and pooled as appropriate 24 h after infection and cell-free 
virus infectivity titers were determined by focus reduction assay in 
MRC5 cell monolayers. The end-point of the assay was the effective 
concentration of compound that reduced virus yield by 50% (EC50) 
compared to untreated virus controls. 
2.4. Statistical analyses 
All data were analyzed using GraphPad Prism (GraphPad Software, 
San Diego, CA). All results are presented as means ± standard de-
viations. The p value was calculated by comparing between % inhibition 
of infected-treated samples with % inhibition of control infected not- 
treated samples and one-tailed Student’s T-test was used to compare 
groups. Significance was reported for p-value < 0.05 (*), <0.01 (**) and 
<0.001 (***). 
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3. Results 
3.1. In silico docking of approved drugs 
For the purpose of known drugs repurposing, a total of 6996 mole-
cules were analyzed from the DrugBank library (https://go.drugbank. 
com/) to target a wide region (~13,300 Å3) around the active site of 
SARS-CoV1 RdRp (PDB-id: 6NUR (Kirchdoerfer and Ward, 2019)). The 
in silico screening was divided into two runs: a fast procedure for the 
selection of the best 2% of the library (118 compounds), with predicted 
binding free energy values (ΔG) from − 8.9 to − 7.6 kcal/mol, followed 
by a more accurate analysis with AutoDock4.2. In this way we ranked 
the 118 known drugs based on the lower ΔG value among the 80 poses 
tested for every compound [between − 11.7 kcal/mol (predicted Ki =
2.7 nM) and − 4.67 kcal/mol (predicted Ki = 377.6 μM)]. The list of the 
first best 60 compounds is reported in supplemental material (Table S1). 
From our list, a reasonable number of compounds was selected for 
cell-based assays (Table 1), taking into account commercial availability 
and solubility properties. Such compounds were also submitted to an 
additional screening (with 300 hybrid GA-LS genetic algorithm runs) 
using the SARS-CoV2 RdRp structures (PDB-id: 6m71) and the scored Ki 
and number of conformations clustered around the one with lower ΔG 
are reported on Table 1. Suramin was added to the list, since it was 
already known to inhibit several RNA viruses such as flavivirus (Basa-
vannacharya and Vasudevan, 2014) (Albulescu et al., 2017), norovirus 
(Mastrangelo et al., 2012, 2014), but also chikungunya and Ebola vi-
ruses (Henβ et al., 2016). 
The best in silico docking pose of lurasidone and elbasvir, in the RdRp 
active site, is reported in Fig. 1A. The protein region explored is located 
between thumb, fingers and palm domains and would host growing 
dsRNA during polymerase activity (Fig. 1A). Such region defines a wide, 
complex and variable hydrophilic protein surface, and it is therefore 
able to host very different types of ligands. In Fig. 1B-E we report the 
details of the lurasidone and elbasvir best docking poses, between the 
thumb and fingers domains, and the schematic view of ligand-protein 
interactions, respectively. 
Since, among the selected compounds, known inhibitors of viral 
proteases (like simeprevir and grazoprevir) were also present, we per-
formed an additional in silico analysis targeting the active site of main 
protease (PDB-id: 6LU7 (Jin et al., 2020)) obtaining the results listed in 
Table 1. Eight of the selected compounds showed predicted binding 
affinity for the protease lower than 50 nM suggesting that such known 
drugs could be in principle active against multiple targets. 
3.2. Antiviral activity against SARS-CoV2 and HCoV-OC43 
The antiviral activity of the selected compounds was assessed against 
two pathogenic CoVs strains: SARS-CoV2 and HCoV-OC43 (Table 2 and 
3, respectively). 
3.2.1. Antiviral activity against SARS-CoV2 
A High Content Assay (HCA) has been developed to test antiviral 
drugs against SARS-CoV2 in vitro. Since a preliminary characterization 
showed sub-optimal infection of Huh7 cells, as also reported elsewhere 
(Ogando et al., 2020), we decided to engineer Huh7 cells carrying the 
human ACE2 receptor. The engineered Huh7-hACE2 cell line supports a 
level of SARS-CoV2 infection suitable for analysis. The assay on 
Huh7-hACE2 was based on immunofluorescence to quantify the number 
of infected Spike-positive cells and the number of nuclei to assess cell 
viability, as shown in Fig. 2. 
The panel of compounds was tested in dose response, and the assay 
was validated using Hydroxychloroquine as reference compound. Re-
sults are reported in Table 2, Fig. 3 and Fig. S2. 
All 14 compounds were tested from a starting concentration of 100 
μM in 2-fold dilutions. 11 compounds showed activity at least in one 
tested concentration. Lurasidone and elbasvir showed the best out-
comes, with EC50 in the micromolar range (18 μM and 23 μM, respec-
tively) and cytotoxicity >1000 μM. Ponatinib and venetoclax reached 
the lowest EC50 (1.1 μM and 6.2 μM, respectively) against SARS-CoV2, 
although the elevated cytotoxicity (CC50 = 8.7 μM and 22.0 μM, 
respectively) indicated poor selectivity index for both compounds 
(calculated as the ratio of the CC50 and the EC50 values). 
The known HCV inhibitors elbasvir, simeprevir and grazoprevir 
showed EC50 values of 23 μM, 9.3 μM and 16 μM, respectively. However, 
their activity as HCV inhibitors is in the low nanomolar range and 
simeprevir showed an unfavorable CC50 of 47.5 μM. The antiviral ac-
tivity of suramin was confirmed, with an EC50 of 64 μM, similarly to 
previous reports (Salgado-Benvindo et al., 2020). A weak activity was 
detected with compounds irinotecan, teniposide and carbenoxolone, all 
with an EC50 around 50–100 μM. In conclusion, our data showed in vitro 
activity for most of the compounds selected in silico against 
SARS-CoV1/2 RdRp. Among all, lurasidone grazoprevir and elbasvir 
showed the best antiviral profile against SARS-CoV2 (Fig. 3). 
Next, to validate the antiviral activity of grazoprevir, lurasidone, 
elbasvir these compounds were further analyzed by virus yield reduction 
assay, a stringent test that measures the ability of a compound to inhibit 
multiple cycles of viral replication and limit the production of infectious 
viral particles. Values of EC50 were obtained based on virus titration and 
normalized with the not-treated control. The three compounds 
confirmed their activity, showing EC50 values similar to those observed 
Table 1 
Compounds selected from in silico docking to be experimentally tested.  
in silico rankinga Cpd drug name ki [nM] RdRp (6nur)a conf. (over 80)b ki [nM] RdRp (6m71)c conf. (over 300)b ki [nM] protease (6lu7)d 
5 DB11363 Alectinib 8.5 6 911.5 51 35.0 
7 DB09042 Tedizolid phosphate 20.2 4 26.9 48 907.6 
9 DB08901 Ponatinib 29.4 2 426.0 24 32.6 
12 DB02329 Carbenoxolone 34.8 17 5.5 32 270.4 
13 DB08815 Lurasidone 64.3 20 110.5 14 7.6 
18 DB01329 Cefoperazone 115.7 4 14.6 15 71.1 
21 DB11574 Elbasvir 167.6 1 69.6 9 1.2 
23 DB00444 Teniposide 204.3 3 3300 12 68.7 
24 DB11581 Venetoclax 208.4 1 9.1 2 0.7 
27 DB00762 Irinotecan 247.6 2 82.8 20 6.7 
32 DB06290 Simeprevir 292.1 4 130.9 12 31.9 
47 DB11575 Grazoprevir 639.9 10 1070 39 40.9 
59 DB00826 Natamycin 945.3 16 2590 9 550.9  
a First screening: selection of drugs using the SARS-CoV1 RdRp. 
b number of poses clustered around the best one (with r.m.s. ≤ 2.0 Å) with lower ΔG (out of 80 or 300 poses for each compound) (Sanner, 1999). 
c Additional screening of the 13 selected drugs using the SARS-CoV2 RdRp. 
d Additional screening of the 13 selected drugs using the SARS-CoV2 main protease. 
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in the high content screening. Grazoprevir demonstrated the highest 
reduction of virus titer, with a reduction of 3.9 logs at the highest con-
centration tested, while lurasidone and elbasvir showed a log reduction 
of 1.3 and 0.6 compared to the not-treated infected control, respectively 
(Table 4). 
3.2.2. Antiviral activity against HCoV-OC43 
In order to evaluate the anti-HCoV-OC43 activity of the selected 
compounds, focus reduction assays were performed on MRC-5 cells, as 
described in the Materials and Methods section and elsewhere (Marcello 
et al., 2020). Results on antiviral activity and cell toxicity are reported in 
Table 3, Fig. 4 and Fig. S3. 
Among the tested compounds, alectinib showed the strongest 
inhibitory activity against HCoV-OC43, with an EC50 in the low micro-
molar range (0.6 μM). Lurasidone and elbasvir also exerted high anti-
viral activity against HCoV-OC43, exhibiting EC50 in the low 
micromolar range: 1.1 μM and 1.5 μM, respectively. A moderate anti-
viral activity was shown by tedizolid, carbenoxolone and suramin, with 
EC50 ranging from 11.0 μM to 94.0 μM. The aforementioned compounds’ 
antiviral effect was not a consequence of cytotoxicity, since none of the 
screened compounds significantly reduced cell viability at any concen-
tration used in the antiviral assays (i.e. up to 100 μM), exhibiting CC50 
Fig. 1. In silico docking analysis A) The best in silico docking pose of lurasidone (sticks with carbon atoms in yellow) and elbasvir (carbon atoms in green) in the 
RdRp region around the protein active site (blue cartoons). Close-up view of the RdRp active site with growing dsRNA (as orange and red cartoons) superimposed. 
B–C) Lurasidone docking site and schematic view of ligand-protein interactions made with program LigPlot (Wallace et al., 1995). D-E) Elbasvir docking site and 
schematic view of ligand-protein interactions. The figure was prepared using PyMOL (The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC). 
Table 2 
HCA for the in silico selected compounds against SARS-CoV2.  
Compound EC50a (μM) (mean ± SD)b CC50c (μM) 
(mean ± SD) 
Alectinib n.a. n.a. 
Tedizolid n.a. n.a. 
Ponatinib 1.1 ± 0.2 8.7 ± 3.8 
Carbenoxolone 66 ± 11 >100 
Lurasidone 18.0 ± 4.6 >1000 
Cefoperazone n.a. n.a. 
Elbasvir 23.0 ± 3.6 >1000 
Teniposide 97.0 ± 0.7 >100 
Venetoclax 6.2 ± 0.6 22.0 ± 6.2 
Irinotecan 85.2 ± 17.0 >100 
Simeprevir 9.3 ± 2.0 47.5 ± 41.0 
Grazoprevir 16.0 ± 5.7 118 ± 6 
Natamycin 24.3 ± 4.4 35.9 ± 13.4 
Suramin 64.0 ± 6.6 >100 
n.a. not assessable. 
a Half maximal effective concentration. 
b Standard deviation. 
c Half maximal cytotoxic concentration. 
Table 3 
Anti-HCoV-OC43 activity of the selected compounds.  
Compound EC50a (μM) 
(mean ± SD)b 
CC50c (μM) 
(mean ± SD) 
Alectinib 0.6 ± 0.2 >1000 
Tedizolid 94.0 ± 25 >1000 
Ponatinib 0.10 ± 0.05 3.1 ± 0.5 
Carbenoxolone 45.7 ± 8.0 251 ± 17 
Lurasidone 1.1 ± 0.4 >1000 
Cefoperazone n.a. >1000 
Elbasvir 1.5 ± 0.5 >1000 
Teniposide n.a. 701 ± 281 
Venetoclax 3.5 ± 0.5 10.6 ± 1.5 
Irinotecan n.a. 63.4 ± 11.4 
Simeprevir 2.1 ± 0.6 11.1 ± 2.3 
Grazoprevir 11.0 ± 1.1 70.0 ± 12.8 
Natamycin n.a. 47.3 ± 4.4 
Suramin 19.3 ± 4.3 >1000 
n.a. not assessable. 
a Half maximal effective concentration. 
b Standard deviation. 
c Half maximal cytotoxic concentration. 
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values higher than 1000 μM. By contrast, the remaining compounds did 
not exhibit interesting features as anti-HCoV-OC43 molecules, due to 
either no antiviral activity (cefoperazone, teniposide, irinotecan, nata-
mycin), or low-moderate selectivity index (ponatinib, venetoclax, 
simeprevir, grazoprevir). In summary, these data showed that alectinib, 
lurasidone and elbasvir were endowed with strong anti-HCoV-OC43 
activity (Fig. 4), with minimal toxicity and selectivity indexes higher 
than 600. 
The antiviral activity of alectinib, lurasidone, and elbasvir was 
further validated by means of virus yield reduction assay. All com-
pounds were found able to effectively reduce HCoV-OC43 yield on MRC- 
5 cell cultures in a dose-dependent manner (Table 4). Specifically, an 
EC50 of 1.0 μM was calculated for alectinib, 8.3 μM for lurasidone, and 
1.3 μM for elbasvir. 
4. Discussion 
An accurate in silico docking search within a wide region around the 
SARS-CoV1/2 RdRp active site, allowed us to select 13 known drugs 
from the DrugBank library to be experimentally tested. We added sur-
amin to the list, a well-known compound able to inhibit different RNA 
viruses (Mastrangelo et al., 2012) (De Clercq, 1979) (Albulescu et al., 
2015). 
To test the in vitro antiviral activity of the selected compounds, cell- 
based assays were established for SARS-CoV2 and HCoV-OC43 using 
Huh7-hACE2 and MRC-5 cells, respectively. Huh7 cells have already 
been widely used for screening purposes, being considered suitable 
model for image processing and being able to support infection of 
several viruses. Since preliminary analysis and previous published data 
indicated a limited infection capacity of SARS-CoV2 in Huh7 cells 
(Ogando et al., 2020), we engineered the human ACE2 receptor in these 
cells to increase infection as previously proposed (Wang et al., 2020) 
Fig. 2. High content screening assay for 
SARS-CoV2. A) Scheme of SARS-CoV2 HCA. 
Huh7-hACE2 were seeded onto 96-well 
plates, after 24 h cells were treated with 
the drugs in two-fold dilutions and immedi-
ately infected with SARS-CoV2 (MOI 0.1). 
20 h after infection, cells were fixed, stained 
and analyzed. B) Representative images of 
the HCA with the control drug hydroxy-
chloroquine (HCQ) (Wang et al., 2020) (Liu 
et al., 2020). Nuclei are stained by DAPI 
(red) and Spike (S) is stained with the 
mSPI-3022 antibody (green), scale bar cor-
responds to 50 μm. C) Dose response of the 
positive control hydroxychloroquine. White 
dots represent the percentage of normalized 
% of inhibition. Blue triangles represent the 
% of nuclei compared to the average % of 
non-infected cells. Error bars represent the 
standard deviation (SD) of 2 independent 
experiments.   
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(Rothan et al., 2020) (Rut et al., 2021). Interestingly, a rather high 
percentage (>60%) of the selected compounds showed some in vitro 
activity against one or both of the tested CoV strains. A possible expla-
nation for such a positive result is related to the characteristics of the 
protein region selected for the in silico docking. Such a portion of the 
protein is a wide, complex and rather hydrophilic surface with many 
conformational degrees of freedom, allowing it to adapt to the growing 
dsRNA during translation. Accordingly, the average crystallographic (or 
cryoEM) conformation of this region must be capable to accommodate 
different kind of ligands, with a preferential affinity for large compounds 
possessing polar/charged moieties and planar aromatic groups: i.e. 
compounds that generally mimic RNA backbone and bases. In other 
words, the in silico docking on RdRp not only selects compounds 
potentially capable of interfering with the polymerase activity but could 
also act as a molecular filter for the selection of properties generally 
favorable for protein binding. This explanation is supported by the 
predicted high affinity of most of the selected compounds for another 
unrelated protein, the main protease of SARS-CoV2 (Table 1). 
Among the tested compounds lurasidone and elbasvir displayed 
higher activity and lower cytotoxicity against both SARS-CoV2 and 
HCoV-OC43 strains. Lurasidone lead to complete inhibition of both 
strains with EC50 values in the micromolar range (18 and 1.1 μM, 
respectively) and favorable selectivity indexes. Lurasidone is an anti-
psychotic drug for treatment of acute depression and schizophrenia, 
known to bind with a low nanomolar affinity to Dopamine-2, 5-HT1A, 5- 
HT2A, and 5-HT7 receptors, and with slightly lower affinity to alpha-2C 
adrenergic receptors (Greenberg and Citrome, 2017). Lurasidone was 
already identified as a potential inhibitor of SARS-CoV2 main protease 
(Elmezayen et al., 2020); (Shamsi et al., 2020), and in our in silico 
analysis it showed good predicted binding affinity for both RdRp and the 
main protease. Furthermore, in a very recent paper, it has been reported 
that lurasidone and its derivatives displayed in silico binding affinity 
against five proteins (Mpro, PLpro, Spro, helicase and RdRp (Thurakkal 
et al., 2021)). Meanwhile, a homologous molecule known as ziprasi-
done, has been shown to lower ACE2 expression in Vero cells and in-
hibits the entry of a pseudotyped retrovirus exposing the SARS-CoV2 
spike protein. Such results indicate that ziprasidone could act against 
SARS-CoV2 by affecting the ACE2 receptor (Massignan et al., 2020). 
Since SARS-CoV2 and HCoV-OC43 share a high level of protein sequence 
conservation (Vijgen et al., 2005) we hypothesize that mechanisms of 
action of lurasidone against these viruses might be the same. 
Elbasvir inhibited SARS-CoV2 and HCoV-OC43 with EC50 values in 
the micromolar range (about 23 and 1.5 μM, respectively). Previous in 
silico studies predicted elbasvir as a high affinity ligand for the RdRp, the 
papain-like protease and the helicase of SARS-CoV2 (Balasubramaniam 
and Shmookler Reis, 2020), whereas our in silico investigation suggested 
a preferential binding for the main protease (predicted Kd = 1.2 nM). In 
combination with grazoprevir (Zepatier), elbasvir has been shown to 
increase 25-fold remdesivir’s apparent potency in preventing 
SARS-CoV2 replication (Nguyenla et al., 2020). Elbasvir is an inhibitor 
of the HCV NS5A protein that has no homologues in coronaviruses: in 
light of our and previous work results, it has the potential to inhibit 
different viral proteins. 
Alectinib showed no activity against SARS-CoV2 but it is the best 
compound against HCoV-OC43 (EC50 = 0.6 μM, CC50 value > 1000 μM). 
In a very recent pre-print paper (Yaron et al., 2020), the authors assert 
that alectinib limits SARS-CoV2 replication in Vero E6, A549-hACE2, 
Calu-3 and primary human pneumocyte cells. The activity was corre-
lated with the lower phosphorylation levels of SRPK1/2, described as a 
required factor for replication of coronaviruses, including SARS-CoV2. 
Fig. 3. Antiviral efficacy of the best selected compounds against SARS- 
CoV2. The antiviral activity was evaluated by the high-content assay infecting 
Huh7-hACE2 cells exposed to increasing amounts of compounds. Number of 
nuclei were quantified in parallel. The percentage infectivity inhibition (white 
dots) was normalized with the average infection ratio of wells treated with 1% 
DMSO. Percentage of nuclei (blue triangles) was calculated by comparing the 
average number of nuclei of non-infected wells treated with 1% DMSO. Error 
bars represent the standard deviation (SD) of 2 independent experiments. *p <
0.05, **p < 0.01, ***p < 0.001 compared between average of % inhibition of 
1%DMSO infected controls and treated-infected of single indicated concentra-
tion, using a one-tailed Student’s T-test. 
Table 4 
Effects of selected compounds on SARS-CoV2 and HCoV-OC43 yield reduction 
and cell viability.  
Compound Virus titer reduction Log10 (mean ± SDa) 










Grazoprevir 3.9 ± 0.07 (100 μM) 3.3 ± 0.9 118 ± 6 
Lurasidone 1.3 ± 0.3 (100 μM) 6.4 ± 3.9 >1000 




Alectinib 2.9 ± 0.1 (33 μM) 1.0 ± 0.1 >1000 
Lurasidone 6.3 ± 1.5 (100 μM) 8.3 ± 2.0 >1000 
Elbasvir 1.4 ± 0.2 (100 μM) 1.3 ± 0.4 >1000 
Virus titer reduction is the difference between log10 values of PFU (SARS-CoV2) 
or FFU/mL (HCoV-OC43) from infected untreated controls and infected-treated 
at the highest tested dose. Mean virus titer for untreated control was 9.8 × 103 
pfu/mL and 3 × 106 FFU/mL for SARS-CoV2 and HCoV-OC43, respectively. 
a Standard deviation. 
b Half maximal effective concentration obtained by virus yield reduction 
assay. 
c Half maximal cytotoxic concentration obtained by Alamar Blue (SARS- 
CoV2) and MTS (HCoV-OC43) assays. 
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Alectinib inhibits the anaplastic lymphoma kinase (ALK) tyrosine kinase 
receptor in the nM range (Kinoshita et al., 2012), binding to the ATP 
binding site of the protein. Therefore, we can speculate that it might 
inhibit other host kinases essential for virus replication in lung epithelia 
and Vero E6 cells, but not in Huh7 cells. 
Grazoprevir inhibited SARS-CoV2 with an EC50 around 16 μM (CC50 
value > 100 μM). Published computational studies suggested grazo-
previr as a potential inhibitor of the nucleocapsid protein or the papain- 
like protease of SARS-CoV2 (Behera et al., 2020). Furthermore, in a very 
recent pre-print report (Bafna et al., 2020) it was shown that grazo-
previr, together with simeprevir, synergizes with the viral polymerase 
inhibitor remdesivir, increasing its inhibitory activity as much as 
10-fold. Grazoprevir is an inhibitor of HCV protease and it is often used 
for therapy in combination with elbasvir (in the drug named zepatier). 
Simeprevir, another inhibitor of HCV protease, has been previously 
shown to inhibit SARS-CoV2 in synergy with remdesivir (Lo et al., 
2020). In our experiments it showed a similar potency against both 
SARS-CoV2 (EC50 about 9.3 μM) and HCoV-OC43 (EC50 about 2.1 μM) 
but with low SI. From our docking results its effect is likely directed 
against the protease, but RdRp inhibition cannot be excluded. 
ABT-199, also known as venetoclax, is a potent selective Bcl2 in-
hibitor, which induces the apoptosis pathway. An early work showed 
that Bcl2 expression prevents SARS-CoV1 induced apoptosis (Bordi 
et al., 2006). In addition, previous reports demonstrated that 
SARS-CoV1 7a protein was dependent on Bcl2 to induce apoptosis, 
suggesting Bcl2 as an important host factor for virus replication and 
pathogenesis (Tan et al., 2007). However, despite its good EC50 (about 
6.2 μM) against SARS-CoV2, venetoclax shows high toxicity in the tested 
cells. 
Ponatinib, an oral drug for the treatment of chronic myeloid leuke-
mia and Philadelphia chromosome-positive acute lymphoblastic leuke-
mia, was already proposed as SARS-CoV2 inhibitor (Nguyen et al., 2020) 
(Sauvat et al., 2020) (Gordon et al., 2020), and it is shown here to inhibit 
SARS-CoV2 and HCoV-OC43 with a poor selective index. 
All the other compounds, although some of them have been 
described in the literature as potential inhibitors of SARS-CoV2 (i.e. 
teniposide (Kadioglu1 et al., n.d.) and irinotecan (B, 2020)), did not 
show any relevant activity in either of the two viruses tested. 
5. Conclusions 
In our work we have: 1. excluded SARS-CoV2 antiviral activity for 
teniposide (Kadioglu1 et al., n.d.) and irinotecan (B, 2020), selected 
from previous computational studies; 2. showed the ability of some of 
the already described anti-SARS-CoV2 compounds to inhibit also coro-
navirus HCoV-OC43 causing the common cold (suramin, ponatinib - 
although with a low SI); and most importantly 3. showed the capability 
of some of the selected drugs to selectively inhibit HCoV-OC43 (alecti-
nib) or SARS-CoV2 (grazoprevir) or be active against both CoV strains 
(lurasidone and elbasvir). The antiviral activity of lurasidone and 
elbasvir was confirmed by virus yield reduction assay for both viruses. 
Treatment of CoV infections with drugs that could inhibit different viral 
targets, as predicted for lurasidone and elbasvir, would be an effective 
way to lower chances of the emergence of drug resistant viral strains. 
Of note, in previous works it was demonstrated that alectinib (Song 
et al., 2015) could penetrate the blood-brain barrier (BBB) exerting its 
activity in the central nervous system (CNS). Since HCoV-OC43, as other 
coronaviruses, is able to invade the CNS (Dubé et al., 2018), alectinib 
might be an interesting candidate for the treatment of HCoV-OC43 
persistent infections in the brain. Moreover, the free levels of alectinib 
found in both plasma and cerebrospinal fluid are similar (Herden and 
Waller, 2018) and its EC50 against HCoV-OC43 (0.6 μM) is lower than 
the maximum level attainable in human serum with daily recommended 
dosage (676 ng/mL corresponding to 1.4 μM) (Ly et al., 2018). 
In conclusion, in this work we showed that lurasidone and elbasvir 
are not only potential drugs against SARS-CoV2, but that they can also 
inhibit the infection established by another beta-CoV, HCoV-OC43. 
Thus, our approach allowed the identification of lead-drugs for further in 
vitro and clinical investigation to contain the present outbreak. 
Furthermore, it could contribute to the identification of broad spectrum 
anti-CoV inhibitors/therapies that would allow for a rapid and effective 
reaction to future epidemics. 
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